---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009138"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:40:57.989255+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics expands board to nine with two new directors

## Summary
- Board increased to nine directors; elected James Shannon, M.D. as Class I director (term expiring at 2025 annual meeting).
- Elected Aoife Brennan, M.D. as Class III director (term expiring at 2027 annual meeting).
- Dr. Shannon appointed to Nominating and Corporate Governance Committee; Dr. Brennan to Audit Committee.
- Both directors to receive standard non-employee director compensation and enter standard indemnification agreement.

## SEC filing metadata
- accession: 0001558370-24-009138
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024009138/0001558370-24-009138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024009138/xlo-20240613x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009138
- JSON: https://secwatch.observer/filing/0001558370-24-009138.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009138.txt

## Key facts
- Executive change
  James Shannon was elected as Class I Director at Xilio Therapeutics, Inc..
  - Action: elected
  - Role: Class I Director
  source text: elected James Shannon, M.D., as a Class I director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837024009138/0001558370-24-009138-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.